Author:
Grieshober Jason A.,Fakunle Eyitayo,Gambardella Ralph A.
Publisher
Springer Berlin Heidelberg
Reference50 articles.
1. Levine D, Mondano L, Halpin M. FDA regulatory pathways for knee cartilage repair products. Sports Med Arthrosc Rev. 2008;16(4):202–7.
2. LaPrade RF, Geeslin AG, Murray IR, et al. Biologic treatments for sports injuries II think tank—current concepts, future research, and barriers to advancement, part 1: biologics overview, ligament injury, tendinopathy. Am J Sports Med. 2016;44:3270–83. doi: 10.1177/0363546516634674 .
3. Barick D. Orthobiologics: is it a game changer in regenerative orthopaedics? Health. 2014;2(4):112–3.
4. Kingham R, Klasa G, Hessler Carver K. Chapter 4: key regulatory guidelines for the development of biologics in the United States and Europe. In: Wang W, Singh M, editors. Biological drug products: development and strategies. 1st ed. New York: Wiley; 2014. p. 75–109.
5. Chirba M, Sweetapple B, Hannon C, Anderson J. FDA regulation of adult stem cell therapies as used in sports medicine. J Knee Surg. 2015;28(01):055–62. doi: 10.1055/s-0034-1398470 .
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献